HL
GMAB icon

Harding Loevner’s Genmab GMAB Stock Holding History

Harding Loevner’s Portfolio GMAB Stock Details GMAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$86.7M Sell
3,231,601
-138,542
-4% -$4.15M 0.89% 36
2025
Q4 		$104M Sell
3,370,143
-114,344
-3% -$3.56M 0.91% 35
2025
Q3 		$107M Buy
3,484,487
+561,048
+19% +$13.7M 0.78% 38
2025
Q2 		$60.4M Buy
2,923,439
+42,613
+1% +$875K 0.41% 55
2025
Q1 		$56.4M Buy
2,880,826
+637,434
+28% +$13.4M 0.43% 52
2024
Q4 		$46.8M Sell
2,243,392
-823,550
-27% -$18.1M 0.32% 52
2024
Q3 		$74.7M Buy
3,066,942
+299,137
+11% +$8M 0.43% 51
2024
Q2 		$69.6M Sell
2,767,805
-526,923
-16% -$14.9M 0.38% 58
2024
Q1 		$98.5M Buy
3,294,728
+4,833
+0.1% +$142K 0.61% 49
2023
Q4 		$97.6M Buy
3,289,895
+85,665
+3% +$2.69M 0.55% 56
2023
Q3 		$113M Buy
3,204,230
+3,036,109
+1,806% +$116M 0.75% 49
2023
Q2 		$6.39M Sell
168,121
-2,029
-1% -$80.9K 0.04% 62
2023
Q1 		$6.43M Buy
170,150
+47,238
+38% +$1.82M 0.04% 68
2022
Q4 		$5.2M Sell
122,912
-6,308
-5% -$260K 0.03% 74
2022
Q3 		$4.15M Sell
129,220
-1,061
-0.8% -$37.3K 0.03% 73
2022
Q2 		$4.24M Sell
130,281
-6,667
-5% -$216K 0.03% 74
2022
Q1 		$4.96M Buy
136,948
+1,827
+1% +$62.7K 0.03% 77
2021
Q4 		$5.34M Buy
135,121
+3,098
+2% +$129K 0.02% 79
2021
Q3 		$5.77M Sell
132,023
-267
-0.2% -$12K 0.02% 77
2021
Q2 		$5.4M Buy
132,290
+13,012
+11% +$502K 0.02% 76
2021
Q1 		$3.92M Sell
119,278
-5,050
-4% -$190K 0.02% 80
2020
Q4 		$5.06M Buy
+124,328
New +$4.65M 0.02% 71

Other funds holding GMAB

OAG
Orbis Allan Gray Hamilton, Bermuda $23.7B AUM 65.43% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Harding Loevner's GMAB Position: Q1 2026 in Review

Harding Loevner reduced its Genmab (GMAB) stake by 4.1% in Q1 2026, selling an estimated $4.15M and leaving 3,231,601 shares worth $86.7M. The position accounts for 0.89% of the portfolio, ranked #36.

Harding Loevner first reported a position in GMAB in Q4 2020 and has held it in 22 quarters since. The position peaked at $113M in Q3 2023. 272 funds tracked by Wall St. Rank hold GMAB as of Q1 2026.

  • Harding Loevner held 3,231,601 shares of Genmab worth $86.7M as of Q1 2026.
  • Harding Loevner sold 138,542 Genmab shares in Q1 2026, an estimated $4.15M.
  • Genmab made up 0.89% of Harding Loevner's portfolio in Q1 2026, its #36 holding.
  • Harding Loevner first reported a position in Genmab in Q4 2020 and has held it in 22 quarters since.
  • Harding Loevner's Genmab position peaked at $113M in Q3 2023.
  • 272 funds tracked by Wall St. Rank held Genmab as of Q1 2026.

Based on Harding Loevner's 13F filing for Q1 2026, filed 15 May 2026.